In Vivo Molecular Fluorescence Imaging - Nanotechnology for Biomedical Imaging and Diagnostics - page 281

9.7 suMMary

In this chapter, we have presented a general overview of existing in vivo fluorescence
imaging techniques. The current demands for better imaging tools in medical diag-
nostics and monitoring of the efficacy of treatments require synthesis of better
fluorescent contrast agents and development of more complicated in vivo optical and
endoscopic equipment and faster and more efficient computational algorithms for
fluorescence optical imaging. In cancer imaging, fluorescence optical tomography
has shown a great promise in diagnostics of the optical signature of cancer lesions.
Targeted fluorescent probes are expected to potentially create new imaging and
treatment paradigms in cancer diagnostics and therapy in the near future.

acknoWledgMents

The authors acknowledge the intramural program of the eunice Kennedy Shriver,
National Institute of Child Health and Human Development, National Institutes of
Health.

reFerences

[1] Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer Sr. emerging
implications of nanotechnology on cancer diagnostics and therapeutics. Cancer
2006; 107 :459-466.
[2] Schroeder A, Heller D, Winslow MM, Dahlman Je, Pratt GW, langer r, Jacks T,
Anderson DG. Treating metastatic cancer with nanotechnology. Nat Rev Cancer
2012; 12 :39-50.
[3] Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer
2005; 5 :161-171.
[4] Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazu V, Borm P, estrada G,
Ntziachristos V, razansky D. Multifunctional nanocarriers for diagnostics, drug delivery
and targeted treatment across blood-brain barrier: perspectives on tracking and neuroim-
aging. Part Fibre Toxicol 2010; 7 :3.
[5] Adams GP, Weiner lM. Monoclonal antibody therapy of cancer. Nat Biotechnol
2005; 23 :1147-1157.
[6] Nelson Al, Dhimolea e, reichert JM. Development trends for human monoclonal
antibody therapeutics. Nat Rev Drug Discov 2010; 9 :767-774.
[7] laudadio J, Quigley DI, Tubbs r, Wolff DJ. Her2 testing: a review of detection method-
ologies and their clinical performance. Expert Rev Mol Diagn 2007; 7 :53-64.
[8] Menard S, Pupa SM, Campiglio M, Tagliabue e. Biologic and therapeutic role of Her2
in cancer. oncogene 2003; 22 :6570-6578.
[9] Moelans CB, de Weger rA, Van der Wall e, van Diest PJ. Current technologies for Her2
testing in breast cancer. Crit Rev oncol Hematol 2011; 80 :380-392.
[10] Au KM, lu Z, Matcher SJ, Armes SP. Polypyrrole nanoparticles: a potential optical coher-
ence tomography contrast agent for cancer imaging. Adv Mater 2011; 23 :5792-5795.